logo

Carglumic Acid Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2026)

The Carglumic Acid Market is segmented by Form (Orally Disintegrating Tablets, Dispersible Tablets, and Others), Distribution Channel and Geography

Home Industry Reports Healthcare Carglumic Acid Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021 - 2 ...

Carglumic Acid Market Snapshot

Carglumic Acid Market
Study Period: 2018 - 2026
Base Year: 2020
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: >7.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The major factors attributing to the growth of the carglumic acid market are the rise in alcohol consumption, smoking and sedentary life leading to various cancers along with with the global prevalence of metabolic disorders like hepatic encephalopathy, Reye’s syndrome, cirrhosis. Thus, resulting in excess levels of ammonia in the blood, resultant higher demand for treatment. For instance, according to the report published by the National Library of Medicine in December 2019, N -acetyl glutamate synthase deficiency is estimated to affect 1 in 2 million people worldwide which fuels the demand for the Carglumic acid globally. Also, carglumic acid has also shown potential for anti-tumor activity in breast cancer, along with various applications in cosmetics, and chemicals which are expected to fuel the global carglumic acid market during the forecast period.

Scope of the Report

Carglumic acid is an orphan drug used to treat hyperammonemia also known as NAGS Syndrome, a rare genetic disorder occurs due to lack of an enzyme called N-acetyl glutamate synthase (NAGS) in the liver results in elevated levels of ammonia in the blood. Various neurological disorders such as congenital deficiencies of urea cycle enzymes, hepatic encephalopathy, Reye’s syndrome, several other metabolic disorders occur with the increased levels of ammonia demanding the necessity for Carglumic acid in the forecast period.

By Dosage Form
Orally Disintegrating Tablets
Dispersible Tablets
Others
By Distribution Channel
Hospital Pharmacies
Retail Pharmacies
E-Commerce Channel
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle-East and Africa
GCC
South Africa
Rest of Middle-East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

Dispersible Tablets Segment is Expected to Hold the Largest Market Share in the Global Carglumic Acid Market

  • The Dispersible Tablets segment holds the largest share in the market attributed to the only approved carbaglu oral dispersible tablet without any generic drug available in the market and increased patient compliance due to its ease of administration. Furthermore, the higher price of the tablets is also expected for its largest revenue that fuels the market throughout the period.
  • Based on Distribution Channel, hospital pharmacies account for the highest revenue in the market due to the availability of the physician, treatment, and medication at a single premise. However, the presence of advanced retail outlets in developed economies also contributed to the growth of the global carglumic acid market. Also, a steep rise in the revenue of carglumic acid through e-commerce channel is a groundbreaking trend that has emerged in the global market in recent years indicating an exponential growth of the global carglumic acid market in the forecast period.
Carglumic Acid Market

North America Dominates the Market and Expected to do Same in the Forecast Period.

North America is expected to dominate the overall carglumic acid market, throughout the forecast period. The dominance is due to several factors such as increasing incidences of various cancers like breast cancer, lung cancer and hyperammonemia in North America leading to high demand for carglumic acid in the region. Also, the presence of key pharmaceutical companies investing in the research activities to develop novel products to treat cancers using the Carglumic acid and the regulatory bodies such as USFDA  create awareness about carglumic acid, along with its dosage and use in the region attributes to the growth of the market. For instance, according to National Center for Biotechnology Information report published in June 2019, about 150,000 patients are newly diagnosed each year with Hepatic encephalopathy in the United States which necessitating a huge demand for treatment propelling the global Carglumic acid market revenue in the forecast period.

Carglumic Acid Market

Competitive Landscape

The global carglumic acid market is moderately competitive and consists of several major players. In terms of market revenue, few of the prominent players currently dominating the market are applying various strategies like acquiring the products or other companies to consolidate their market positions across the globe and while others are applying for generic product approvals. For example, a rise in API manufacturers like Suven and Apothecan in India generates revenue by supplying the API to meet the demand of carglumic acid driving the market growth. Some of the companies which are currently dominating the market are Apothecon Pharmaceuticals Pvt. Ltd, Manus Aktteva Biopharma LLP, Recordati Rare Diseases Inc, Dipharma Francis S.r.l and Civentichem LLC.

Carglumic Acid Market

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Increasing Global Prevalence of N-acetylglutamate Synthase (NAGS) Syndrome and Cancer Cases

      2. 4.2.2 Rise in New Product Approvals due to Accelerated Drug Approval Initiative by USFDA

    3. 4.3 Market Restraints

      1. 4.3.1 Higher Challenges in Development Stage and Expensive Patented Products

      2. 4.3.2 Severe Adverse Effects Associated with Carglumic Acid Medication

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Dosage Form

      1. 5.1.1 Orally Disintegrating Tablets

      2. 5.1.2 Dispersible Tablets

      3. 5.1.3 Others

    2. 5.2 By Distribution Channel

      1. 5.2.1 Hospital Pharmacies

      2. 5.2.2 Retail Pharmacies

      3. 5.2.3 E-Commerce Channel

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle-East and Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle-East and Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Apothecon Pharmaceuticals Pvt Ltd

      2. 6.1.2 Manus Aktteva Biopharma LLP

      3. 6.1.3 Recordati Rare Diseases Inc

      4. 6.1.4 Dipharma Francis S r l

      5. 6.1.5 Civentichem LLC

      6. 6.1.6 Dipharma S A

      7. 6.1.7 NURAY CHEMICALS

      8. 6.1.8 NOVITIUM PHARMA LLC

      9. 6.1.9 Suven Life Sciences Limited

      10. 6.1.10 Biophore India Pharmaceuticals Pvt Ltd

      2. *List Not Exhaustive

  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Carglumic Acid Market market is studied from 2018 - 2026.

The Carglumic Acid Market is growing at a CAGR of >7.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2020.

Apothecon Pharmaceuticals Pvt. Ltd, Manus Aktteva Biopharma LLP, Recordati Rare Diseases Inc, Dipharma Francis S.r.l, Civentichem LLC are the major companies operating in Carglumic Acid Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!